Donate
Hemangiosarcoma is a devastatingly
common cancer.
Step by step, we are progressing toward a better tomorrow for this prognosis, but right now, the best source of support we have is each other.
By donating to our mission, you can help push forward the clinical trial that may unveil the next breakthrough or come to the aid of families who cannot afford the treatment that could give them some precious extra time to enjoy with their pups.
Give in Honor & Give in Memory
The love we share with our dogs is expansive.
Giving in honor to mark a special milestone or in memory of your wonderful pet is a beautiful way to celebrate them. Your tribute to your dog can make a significant difference in the life of another.
You can share more about your story in the donation form, and if you want to, we’d love a picture of your dear canine companion to feature on our memory wall.
Additional Ways to Give
We gladly accept donations through corporate sponsorships from committed organizations and matching employee gifts to amplify the impact of your support. If you’d like to donate in another way, please contact us.
Recent Updates
The Pain of Knowing: Coping with Anticipatory Grief
The flood of emotions that come with your dog's hemangiosarcoma diagnosis doesn’t come with any warnings. One of the first and most...
Can Your Anxiety Affect Your Dog?
Caring for a dog with hemangiosarcoma is tough. Here’s how your emotional health may be affecting theirs.
Canine Chemotherapy: Myths, Truths, and Everything In Between
There are many misconceptions and old beliefs that veterinarians and researchers are fighting to demystify.
Toxicity Profile of eBAT in Hemangiosarcoma
This study evaluates the safety and efficacy of eBAT in treating dogs with hemangiosarcoma, showing promising results with mild side effects and potential to prolong survival.
Pleiotropic Effects of Resveratrol on Cardiovascular Diseases in Dogs
This study explores how resveratrol supplementation may reduce chemotherapy-induced cardiac toxicity in dogs while enhancing anti-tumor effects in hemangiosarcoma.
Autologous Dendritic Cell Therapy in Stage II Hemangiosarcoma
The group that received full dendritic cell therapy had a median survival of 256 days, with a 29% one-year survival rate.